PTPN22 and cancer: On the one hand, the RNAi was combined with the carbon nanotubes to achieve passive tumour targeting by virtue of EPR effect in cancer, and on the other hand, we further modified the surface of functionalized CNTs with LyP‐1 to attain active tumour targeting in PDAC, which resulted from the affinity ability of LyP‐1 peptides with BxPC‐3 cells.